High-dose testosterone and a drug for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced prostate cancer that has spread to other parts of your body.
- Your cancer has been getting worse while on treatment with abiraterone.
- You are able to walk and care for yourself (performance status 0-2).
- Your kidneys, liver, and blood counts are within acceptable ranges.
- If you have tumors that can be safely biopsied, you agree to have biopsies before and during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of hormone therapy, chemotherapy (docetaxel), and a targeted drug (apalutamide) with a focused ultrasound procedure (HIFU) for men with prostate cancer that has spread to many bones or organs. It may help control the cancer more effectively.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
This trial tests whether giving a high dose of testosterone before standard hormone therapy can help the treatment work longer for men with prostate cancer that has spread. You would receive testosterone injections for a short time, then a hormone blocker (darolutamide) along with continued testosterone shots.
This trial tests a new combination of drugs (ZEN-3694 and enzalutamide) for men with advanced prostate cancer that has stopped responding to standard hormonal treatments. It aims to see if this combination can help slow or stop the cancer from growing.
This trial tests a new combination treatment for men with advanced prostate cancer that has stopped responding to usual hormone therapy. It compares high-dose testosterone followed by darolutamide to standard care, and may help control the cancer longer.
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.